{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:58:00Z","timestamp":1793321880160,"version":"4.5.0"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,10,13]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn\u2019s disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, postexertional malaise, pain and autonomic and neurocognitive disturbances. This series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome shows the range of responses they observed when taking LDN, from life changing to a reduction in some symptoms only. Treatment doses ranged from 4 to 12\u2009mg. Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available.<\/jats:p>","DOI":"10.1136\/bcr-2019-232502","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T09:22:09Z","timestamp":1579598529000},"page":"e232502","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["Low-dose naltrexone as a treatment for chronic fatigue syndrome"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7972-1841","authenticated-orcid":false,"given":"Monica Jane","family":"Bolton","sequence":"first","affiliation":[{"name":"Patient, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan Paul","family":"Chapman","sequence":"additional","affiliation":[{"name":"Patient, West Sussex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Van Marwijk","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"2025082723402389000_13.1.e232502.1","unstructured":"Institute of Medicine . Beyond myalgic Encephalomyelitis\/Chronic fatigue syndrome: redefining an illness, 2015. Available: https:\/\/www.iom.edu\/Reports\/2015\/ME-CFS.aspx [Accessed 1 Jun 2015]."},{"key":"2025082723402389000_13.1.e232502.2","article-title":"Two age peaks in the incidence of chronic fatigue syndrome\/myalgic encephalomyelitis: a population-based registry study from Norway 2008-2012","volume":"12","author":"Bakken","year":"2014","journal-title":"BMC Med"},{"key":"2025082723402389000_13.1.e232502.3","doi-asserted-by":"publisher","DOI":"10.1177\/0141076817702530"},{"key":"2025082723402389000_13.1.e232502.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.18.2129"},{"key":"2025082723402389000_13.1.e232502.5","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-9-91","article-title":"Prevalence of myalgic Encephalomyelitis\/Chronic fatigue syndrome (ME\/CFS) in three regions of England: a repeated cross-sectional study in primary care","volume":"9","author":"Nacul","year":"2011","journal-title":"BMC Med"},{"key":"2025082723402389000_13.1.e232502.6","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqi013"},{"key":"2025082723402389000_13.1.e232502.7","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-402","article-title":"The functional status and well being of people with myalgic Encephalomyelitis\/Chronic fatigue syndrome and their carers","volume":"11","author":"Nacul","year":"2011","journal-title":"BMC Public Health"},{"key":"2025082723402389000_13.1.e232502.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132421","article-title":"The health-related quality of life for patients with myalgic encephalomyelitis \/ chronic fatigue syndrome (ME\/CFS)","volume":"10","author":"Falk Hvidberg","year":"2015","journal-title":"PLoS One"},{"key":"2025082723402389000_13.1.e232502.9","unstructured":"Radford G , Chowdhury S . Me\/Cfs research funding an overview of activity by major institutional funders included on the dimensions database, 2016."},{"key":"2025082723402389000_13.1.e232502.10","unstructured":"Action for ME . Ignorance, injustice and neglect. An investigation into NHS specialist service provision for people with ME\/CFS. Bristol, 2012. Available: http:\/\/www.actionforme.org.uk\/OneStopCMS\/Core\/CrawlerResourceServer.aspx?resource=f11e86c4-9ca3-4185-9934-e43f7e4b3bec"},{"key":"2025082723402389000_13.1.e232502.11","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S1386-6532(06)70009-9","article-title":"Use of valganciclovir in patients with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue","volume":"37 Suppl 1","author":"Kogelnik","year":"2006","journal-title":"J Clin Virol"},{"key":"2025082723402389000_13.1.e232502.12","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq094"},{"key":"2025082723402389000_13.1.e232502.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031334","article-title":"A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome","volume":"7","author":"Strayer","year":"2012","journal-title":"PLoS One"},{"key":"2025082723402389000_13.1.e232502.14","unstructured":"Johnson C . Norwegian rituximab chronic fatigue syndrome (ME\/CFS) trial fails. Simmaron Res, 2017. Available: http:\/\/simmaronresearch.com\/2017\/11\/norwegian-rituximab-chronic-fatigue-syndrome-mecfs-trial-fails\/ [Accessed 10 Aug 2018]."},{"key":"2025082723402389000_13.1.e232502.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.04.038"},{"key":"2025082723402389000_13.1.e232502.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1207-3"},{"key":"2025082723402389000_13.1.e232502.17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.intimp.2016.08.015","article-title":"Functional modulation on macrophage by low dose naltrexone (LDN)","volume":"39","author":"Yi","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"2025082723402389000_13.1.e232502.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.06.016"},{"key":"2025082723402389000_13.1.e232502.19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/ijo.2016.3567","article-title":"Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy","volume":"49","author":"Liu","year":"2016","journal-title":"Int J Oncol"},{"key":"2025082723402389000_13.1.e232502.20","article-title":"Low-Dose Naltrexone (LDN)\u2014review of therapeutic utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci"},{"key":"2025082723402389000_13.1.e232502.21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"2025082723402389000_13.1.e232502.22","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510366857"},{"key":"2025082723402389000_13.1.e232502.23","first-page":"132","article-title":"Double-Blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War illness","volume":"6","author":"Brewer","year":"2018","journal-title":"Fatigue: Biomedicine, Health & Behavior"},{"key":"2025082723402389000_13.1.e232502.24","first-page":"189","article-title":"Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV + adults in Mali\u202f: a single blind randomized clinical trial","volume":"3","author":"Traore","year":"2011","journal-title":"J AIDS HIV Res"},{"key":"2025082723402389000_13.1.e232502.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1653-7"},{"key":"2025082723402389000_13.1.e232502.26","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182702f2b"},{"key":"2025082723402389000_13.1.e232502.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.37734"},{"key":"2025082723402389000_13.1.e232502.28","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.2126","article-title":"SAT0402\u2005Efficacy of Naltrexone in the Treatment of Fibromyalgia: Randomized Controlled Trial","volume":"72","author":"Abou-Raya","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025082723402389000_13.1.e232502.29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ecco-jcc\/jjy008","article-title":"The effect of low-dose naltrexone on medication in inflammatory bowel disease: a Quasi experimental before-and-after prescription database study","volume":"12","author":"Raknes","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025082723402389000_13.1.e232502.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212460","article-title":"Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study","volume":"14","author":"Raknes","year":"2019","journal-title":"PLoS One"},{"key":"2025082723402389000_13.1.e232502.31","unstructured":"Wouk J . LDN World Database - CFS\/ME, 2019. Available: http:\/\/www.ldndatabase.com\/cfs.html [Accessed 7 May 2019]."},{"key":"2025082723402389000_13.1.e232502.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2003.10.004"},{"key":"2025082723402389000_13.1.e232502.33","doi-asserted-by":"publisher","DOI":"10.1037\/h0054651"},{"key":"2025082723402389000_13.1.e232502.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6177(03)00039-8"},{"key":"2025082723402389000_13.1.e232502.35","doi-asserted-by":"publisher","DOI":"10.1076\/clin.13.1.30.1976"},{"key":"2025082723402389000_13.1.e232502.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02428.x"},{"key":"2025082723402389000_13.1.e232502.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2025082723402389000_13.1.e232502.38","doi-asserted-by":"publisher","DOI":"10.1177\/1367493505049644"},{"key":"2025082723402389000_13.1.e232502.39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1535370217749830","article-title":"Featured article: modulation of the OGF\u2013OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"243","author":"Ludwig","year":"2018","journal-title":"Exp Biol Med"},{"key":"2025082723402389000_13.1.e232502.40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00809","article-title":"Naltrexone inhibits IL-6 and TNF\u03b1 production in human immune cell subsets following stimulation with ligands for intracellular Toll-like receptors","volume":"8","author":"Cant","year":"2017","journal-title":"Front Immunol"},{"key":"2025082723402389000_13.1.e232502.41","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2007.57"},{"key":"2025082723402389000_13.1.e232502.42","unstructured":"LDN Research Trust conference . Dr. Tom Gilhooly - YouTube, 2013. Available: https:\/\/www.youtube.com\/watch?v=G6SWv7HEj8M [Accessed 27 Mar 2019]."},{"key":"2025082723402389000_13.1.e232502.43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M18-1451","article-title":"B-Lymphocyte depletion in patients with myalgic Encephalomyelitis\/Chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial","volume":"170","author":"Fluge","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025082723402389000_13.1.e232502.44","unstructured":"Dickson S . Low dose naltrexone 2018 information pack, 2018. Available: https:\/\/www.ldnresearchtrust.org\/sites\/default\/files\/LDN-2018-Fact Sheet-UK-Europe.pdf [Accessed 3 May 2019]."},{"key":"2025082723402389000_13.1.e232502.45","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.01033","article-title":"Neuroinflammation and cytokines in myalgic Encephalomyelitis\/Chronic fatigue syndrome (ME\/CFS): a critical review of research methods","volume":"9","author":"VanElzakker","year":"2018","journal-title":"Front Neurol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:40:36Z","timestamp":1756363236000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,6]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/bcr-2019-232502"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232502","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}